S. Mcguire, World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015, Advances in Nutrition: An International Review Journal, vol.7, issue.2, pp.418-419, 2015.
DOI : 10.3945/an.116.012211

G. Köhler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, vol.3, issue.5517, pp.495-497, 1975.
DOI : 10.1042/bj1280427

A. Lacassagne, Advances in radiobiology between 1937 and 1950, Nucleonics, vol.7, pp.62-67, 1950.

D. Goldenberg, F. Deland, and E. Kim, Use of Radio-Labeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning, New England Journal of Medicine, vol.298, issue.25, pp.1384-1386, 1978.
DOI : 10.1056/NEJM197806222982503

M. Herlyn, Z. Steplewski, and D. Herlyn, Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies., Proceedings of the National Academy of Sciences, vol.76, issue.3, pp.1438-1442, 1979.
DOI : 10.1073/pnas.76.3.1438

S. Denardo, G. Denardo, O. Grady, and L. , McGahan JP: treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies, Int J Biol Markers, vol.2, pp.49-53, 1987.

B. Khaw, J. Cooney, and T. Edgington, Strauss HW: differences in experimental tumor localization of dual-labeled monoclonal antibody, J Nucl Med, vol.27, pp.1293-1299, 1986.

W. Cole, S. Denardo, and C. Meares, Moi MK: comparative serum stability of radiochelates for antibody radiopharmaceuticals, J Nucl Med, vol.28, pp.83-90, 1987.

D. Goodwin, C. Meares, and M. Mccall, Chaovapong W: chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse, J Nucl Med, vol.26, pp.493-502, 1985.

S. Deshpande, S. Denardo, and D. Kukis, Meares CF: yttrium-90- labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent, J Nucl Med, vol.31, pp.473-479, 1990.

S. Siberil, C. Dutertre, and C. Boix, Anticorps monoclonaux ?? usage th??rapeutique??: un peu d'histoire, beaucoup d'ing??nierie, et ??? quelques succ??s cliniques, Transfusion Clinique et Biologique, vol.12, issue.2, pp.114-122, 2005.
DOI : 10.1016/j.tracli.2005.04.016

O. Press, J. Leonard, and B. Coiffier, Immunotherapy of Non-Hodgkin's Lymphomas, Hematology, vol.2001, issue.1, pp.221-240, 2001.
DOI : 10.1182/asheducation-2001.1.221

D. Slamon, L. , B. Shak, and S. , Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, New England Journal of Medicine, vol.344, issue.11, pp.783-792, 2001.
DOI : 10.1056/NEJM200103153441101

B. Cheson, Radioimmunotherapy of non-Hodgkin lymphomas, Blood, vol.101, issue.2, pp.391-398, 2003.
DOI : 10.1182/blood-2002-06-1793
URL : http://www.bloodjournal.org/content/bloodjournal/101/2/391.full.pdf

J. Brown and . Giaccia, AJ: the unique physiology of solid tumors: opportunities (and problems) for cancer therapy, Cancer Res, vol.58, pp.1408-1416, 1998.

M. Konerding and E. Fait, 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon, British Journal of Cancer, vol.84, issue.10, pp.1354-1362, 2001.
DOI : 10.1054/bjoc.2001.1809

P. Netti, L. Hamberg, and J. Babich, Enhancement of fluid filtration across tumor vessels: Implication for delivery of macromolecules, Proceedings of the National Academy of Sciences, vol.56, issue.5, pp.3137-3142, 1999.
DOI : 10.1161/01.RES.71.4.978

M. Tabrizi, G. Bornstein, and H. Suria, Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease, The AAPS Journal, vol.12, issue.1, pp.33-43, 2010.
DOI : 10.1208/s12248-009-9157-5

G. Thurber and M. Schmidt, Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance, Advanced Drug Delivery Reviews, vol.60, issue.12, pp.1421-1434, 2008.
DOI : 10.1016/j.addr.2008.04.012
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820307/pdf

F. Chen, A. Epstein, and Z. Li, Taylor CR: a comparative autoradiographic study demonstrating differential intratumor localization of monoclonal antibodies to cell surface (Lym-1) and intracellular (TNT-1) antigens, J Nucl Med, vol.31, pp.1059-1066, 1990.

P. Hu, J. Hornick, and M. Glasky, A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake, Cancer Res, vol.56, pp.4998-5004, 1996.

B. Leberthon, L. Khawli, and M. Alauddin, Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate, Cancer Res, vol.51, pp.2694-2698, 1991.

L. Khawli, M. Glasky, and M. Alauddin, Improved Tumor Localization and Radioimaging with Chemically Modified Monoclonal Antibodies, Cancer Biotherapy & Radiopharmaceuticals, vol.11, issue.3, pp.203-215, 1996.
DOI : 10.1089/cbr.1996.11.203

L. Khawli, M. Mizokami, and J. Sharifi, Pharmacokinetic Characteristics and Biodistribution of Radioiodinated Chimeric TNT-1, -2, and -3 Monoclonal Antibodies After Chemical Modification with Biotin, Cancer Biotherapy & Radiopharmaceuticals, vol.17, issue.4, pp.359-370, 2002.
DOI : 10.1089/108497802760363150

J. Sharifi, L. Khawli, and J. Hornick, Improving monoclonal antibody pharmacokinetics via chemical modification, Q J Nucl Med, vol.42, pp.242-249, 1998.

A. Murtha, Radiobiology of Low-Dose-Rate Radiation Relevant to Radioimmunotherapy, Cancer Biotherapy & Radiopharmaceuticals, vol.15, issue.1, pp.7-14, 2000.
DOI : 10.1089/cbr.2000.15.7

J. Pouget, C. Lozza, and E. Deshayes, Navarro-Teulon I: introduction to radiobiology of targeted radionuclide therapy, Front Med (Lausanne), vol.2, p.12, 2015.

T. Bäck, B. Haraldsson, and R. Hultborn, : A Long-Term Study of Renal Function in Nude Mice, Cancer Biotherapy & Radiopharmaceuticals, vol.24, issue.6, pp.649-658, 2009.
DOI : 10.1089/cbr.2009.0628

H. Andersson, E. Cederkrantz, and T. Bäck, Intraperitoneal ??-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study, Journal of Nuclear Medicine, vol.50, issue.7, pp.1153-1160, 2009.
DOI : 10.2967/jnumed.109.062604

K. Lam, C. Chan, and R. Reilly, for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT, mAbs, vol.46, issue.1, pp.154-164, 2017.
DOI : 10.2967/jnumed.109.072389

M. Ueda, H. Hisada, and T. Temma, Gallium-68-Labeled Anti-HER2 Single-Chain Fv Fragment: Development and In Vivo Monitoring of HER2 Expression, Molecular Imaging and Biology, vol.53, issue.Suppl 2, pp.102-110, 2015.
DOI : 10.2967/jnumed.111.096685

S. Knowles, K. Zettlitz, and R. Tavaré, Quantitative ImmunoPET of Prostate Cancer Xenografts with 89Zr- and 124I-Labeled Anti-PSCA A11 Minibody, Journal of Nuclear Medicine, vol.55, issue.3, pp.452-459, 2014.
DOI : 10.2967/jnumed.113.120873

J. Barbet, F. Kraeber-bodéré, and J. Vuillez, Pretargeting with the Affinity Enhancement System for Radioimmunotherapy, Cancer Biotherapy & Radiopharmaceuticals, vol.14, issue.3, pp.153-166, 1999.
DOI : 10.1089/cbr.1999.14.153

F. Kraeber-bodéré, C. Rousseau, and C. Bodet-milin, Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial, J Nucl Med, vol.47, pp.247-255, 2006.

P. Salaun, L. Campion, and C. Bournaud, Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement, Journal of Nuclear Medicine, vol.53, issue.8, pp.1185-1192, 2012.
DOI : 10.2967/jnumed.111.101865
URL : https://hal.archives-ouvertes.fr/hal-00932253

P. Salaun, L. Campion, and C. Ansquer, 18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma, European Journal of Nuclear Medicine and Molecular Imaging, vol.30, issue.3, pp.1501-1510, 2014.
DOI : 10.1200/JCO.2012.42.3160

D. Goldenberg, E. Rossi, and R. Sharkey, Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting, Journal of Nuclear Medicine, vol.49, issue.1, pp.158-163, 2008.
DOI : 10.2967/jnumed.107.046185

C. Bodet-milin, A. Faivre-chauvet, and T. Carlier, Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial, Journal of Nuclear Medicine, vol.57, issue.10, pp.1505-1511, 2016.
DOI : 10.2967/jnumed.116.172221
URL : https://hal.archives-ouvertes.fr/inserm-01415668

C. Bodet-milin, L. Ferrer, and A. Rauscher, Pharmacokinetics and Dosimetry Studies for Optimization of Pretargeted Radioimmunotherapy in CEA-Expressing Advanced Lung Cancer Patients, Frontiers in Medicine, vol.38, issue.12, p.84, 2015.
DOI : 10.1007/s00259-011-1903-0
URL : https://hal.archives-ouvertes.fr/hal-01258870

B. Ng, E. Kramer, and L. Liebes, Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts, Cancer Res, vol.61, pp.2996-3001, 2001.

T. Cardillo, R. Blumenthal, and Z. Ying, Gold DV: combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer

S. Supiot, S. Gouard, and J. Charrier, Mechanisms of Cell Sensitization to ?? Radioimmunotherapy by Doxorubicin or Paclitaxel in Multiple Myeloma Cell Lines, Clinical Cancer Research, vol.11, issue.19, pp.7047-7052, 2005.
DOI : 10.1158/1078-0432.CCR-1004-0021

B. Jang, S. Lee, and H. Kim, Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab, Nuclear Medicine and Biology, vol.39, issue.4, pp.472-483, 2012.
DOI : 10.1016/j.nucmedbio.2011.10.020

R. Elstrom, J. Ruan, and P. Christos, Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab

J. Mortimer, J. Bading, and D. Colcher, Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET, Journal of Nuclear Medicine, vol.55, issue.1, pp.23-29, 2014.
DOI : 10.2967/jnumed.113.122630

C. Menke-van-der-houven-van-oordt, E. Gootjes, and M. Huisman, 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer, Oncotarget, vol.6, pp.30384-30393, 2015.

S. Tagawa, M. Milowsky, and M. Morris, Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer, Clinical Cancer Research, vol.19, issue.18, pp.5182-5191, 2013.
DOI : 10.1158/1078-0432.CCR-13-0231

P. Bhusari, R. Vatsa, and G. Singh, Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients, International Journal of Cancer, vol.87, issue.4, pp.938-947, 2017.
DOI : 10.1038/clpt.2010.12

M. Kameswaran, U. Pandey, and C. Dhakan, Lu-CHX-A???-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma, Cancer Biotherapy and Radiopharmaceuticals, vol.30, issue.6, pp.240-246, 2015.
DOI : 10.1089/cbr.2015.1836

C. Featherstone, ??-Particle-emitting radioisotopes coupled to antibody for acute myeloid leukaemia treatment, Molecular Medicine Today, vol.3, issue.6, pp.232-233, 1997.
DOI : 10.1016/S1357-4310(97)89505-6

M. Zalutsky, D. Reardon, and G. Akabani, Clinical Experience with ??-Particle Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6, Journal of Nuclear Medicine, vol.49, issue.1, pp.30-38, 2008.
DOI : 10.2967/jnumed.107.046938

G. Denardo, J. Schlom, and D. Buchsbaum, Rationales, evidence, and design considerations for fractionated radioimmunotherapy, Cancer, vol.41, issue.S4, pp.1332-1348, 2002.
DOI : 10.4049/jimmunol.164.3.1432

T. Illidge, S. Mayes, and R. Pettengell, Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria, Journal of Clinical Oncology, vol.32, issue.3, pp.212-218, 2014.
DOI : 10.1200/JCO.2013.50.3110

C. Scholz, A. Pinto, and W. Linkesch, Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial, Journal of Clinical Oncology, vol.31, issue.3, pp.308-313, 2013.
DOI : 10.1200/JCO.2011.41.1553

F. Kraeber-bodéré, A. Pallardy, and H. Maisonneuve, Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trial, The Lancet Haematology, vol.4, issue.1, pp.35-45, 2017.
DOI : 10.1016/S2352-3026(16)30168-5

M. Hettich, F. Braun, and M. Bartholomä, High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers, Theranostics, vol.6, issue.10, pp.1629-1640, 2016.
DOI : 10.7150/thno.15253
URL : http://www.thno.org/v06p1629.pdf

J. Ménager, J. Gorin, and C. Maurel, Combining ??-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction, PLOS ONE, vol.62, issue.Suppl 1, p.130249, 2015.
DOI : 10.1371/journal.pone.0130249.s001